相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
Niklas W. Andersson et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
Stuart J. Connolly et al.
LANCET (2018)
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the US Department of Defense Population
Kiran Gupta et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation
Tony Antoniou et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2017)
Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC)
Annie Herbert et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2017)
Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
Shang-Hung Chang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study
Emilie M. Gieling et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPACE (2016)
Drug-drug interactions of non-vitamin K oral anticoagulants
Christos Voukalis et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Why switch from warfarin to NOACs?
Paolo Verdecchia et al.
INTERNAL AND EMERGENCY MEDICINE (2016)
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Charles E. Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
Hein Heidbuchel et al.
EUROPACE (2015)
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Emily Herrett et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2015)
Effect of Selective Serotonin Reuptake Inhibitors on Bleeding Risk in Patients With Atrial Fibrillation Taking Warfarin
Gene R. Quinn et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial
Benjamin A. Steinberg et al.
HEART RHYTHM (2014)
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions
J. W. Cheng et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial
Greg Flaker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
In Vitro Predictability of Drug-Drug Interaction Likelihood of P-Glycoprotein-Mediated Efflux of Dabigatran Etexilate Based on [I]2/IC50 Threshold
Wataru Kishimoto et al.
DRUG METABOLISM AND DISPOSITION (2014)
Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects
Sebastian Haertter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
Sebastian Haertter et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
Dagmar Kubitza et al.
PHARMACEUTICALS (2012)
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Mark Jean Gnoth et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Validation and validity of diagnoses in the General Practice Research Database: a systematic review
Emily Herrett et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length
Helga Gardarsdottir et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2010)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins
Tom Schalekamp et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
分享论文
